|

ETX-636 dose expansion in combination with fulvestrant Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Faslodex

Pipeline

Phase 1/2: 1

Top Sponsors

  • Ensem Therapeutics1

Indications

  • Advanced Breast Cancer1
  • Advanced Solid Tumors1
  • Breast Cancer1
  • Cancer1

Newport Beach, California1 trial

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Hoag Memorial Hospital Presbyterian

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.